Niagen Bioscience, Inc. Unknown
Niagen Bioscience, Inc. (Nasdaq: Unknown) is a rare genetic drug developer. Its lead program, NB4168, is in Pre-clinical for Ataxia-Telangiectasia (A-T).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NB4168 | Ataxia-Telangiectasia | small molecule | Pre-clinical |
Recent results and decisions
- Aug 4, 2026approval NB4168 received Rare Pediatric Disease designation from the FDA and Orphan Medicinal Product Designation from the EMA for the treatment of Ataxia-Telangiectasia.
NB4168 received the Rare Pediatric Disease (RPD) designation for the treatment of A-T from the U.S. Food and Drug Administration, and Orphan Medicinal Product Designation (OMPD) from the European Medicines Agency (EMA), supporting the Company's plans to advance the program globally.
Filing - Aug 4, 2026started Niagen Bioscience engaged Evotec as CRO for preclinical and IND enabling studies for NB4168, anticipated to begin in Q3 2026.
Engaged Evotec as its contract research organization for the preclinical and IND enabling studies for NB4168, anticipated to begin in Q3 2026.
Filing - Aug 4, 2026n/a NB4168 received Rare Pediatric Disease designation from the FDA and Orphan Medicinal Product Designation from the EMA for treatment of Ataxia-Telangiectasia.
NB4168 received the Rare Pediatric Disease (RPD) designation for the treatment of A-T from the U.S. Food and Drug Administration, and Orphan Medicinal Product Designation (OMPD) from the European Medicines Agency (EMA).
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical rare genetic companies
- Abeona Therapeutics Inc. ABEO
- Korro Bio, Inc. KRRO
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.